metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Cribado de la enfermedad celíaca en grupos de riesgo
Información de la revista
Vol. 28. Núm. 9.
Páginas 561-566 (noviembre 2005)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. 9.
Páginas 561-566 (noviembre 2005)
Progresos en gastroenterología
Acceso a texto completo
Cribado de la enfermedad celíaca en grupos de riesgo
Screening for celiac disease in high risk groups
Visitas
7966
F. Fernández-Bañares
Autor para correspondencia
digestiu@mutuaterrassa.es

Correspondencia: Dr. F. Fernández-Bañares. Servicio de Aparato Digestivo. Hospital Universitari Mútua Terrassa. Pl. Dr. Robert, 5. 08221 Terrassa. Barcelona. España.
, M. Esteve-Comas, M. Rosinach
Servicio de Aparato Digestivo. Hospital Universitari Mútua Terrassa. Barcelona. España
Este artículo ha recibido
Información del artículo
Resumen

Diversos estudios epidemiológicos muestran que la enfermedad celíaca con manifestaciones extraintestinales es 15 veces más frecuente que la que se presenta con síntomas intestinales. Hace ya años que se propuso el «modelo del iceberg» para explicar la epidemiología de la enfermedad celíaca. Por un lado, hay un número cuantificable de pacientes que son correctamente diagnosticados porque presentan síntomas sugestivos y forman la parte visible del iceberg. Sin embargo, diversos estudios, que emplean técnicas de cribado mediante serología, demuestran que por cada paciente diagnosticado, hay una media de 5-10 casos que no lo estaban. Estos casos forman la parte sumergida del iceberg (enfermedad celíaca monosintomática o silenciosa). La estrategia más aceptada para investigar la porción sumergida del «iceberg celíaco» es el cribado de grupos de riesgo reconocidos, mediante un proceso de búsqueda sistemática de enfermedad celíaca.

Several epidemiological studies show that celiac disease with extraintestinal manifestations is 15 times more frequent than celiac disease with intestinal symptoms. Fifteen years ago the iceberg model was proposed to explain the epidemiology of this disease. On the one hand, there are a quantifiable number of patients who are correctly diagnosed since they have symptoms suggestive of this disease and who form the visible part of the iceberg. However, several studies using screening serology demonstrate that for each patient diagnosed, there is a mean of 5-10 patients without a diagnosis. These patients form the submerged part of the iceberg (monosymptomatic or silent celiac disease). The most widely accepted strategy to investigate the submerged part of the “celiac iceberg” is screening of known risk groups through a systematic search for celiac disease in these groups.

El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Fasano, C. Catassi.
Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum.
Gastroenterology, 120 (2001), pp. 636-651
[2.]
S. Riestra, E. Fernández, L. Rodrigo, et al.
Prevalence of celiac disease in the general population of Northern Spain. Strategies of serologic screening.
Scand J Gastroenterol, 35 (2000), pp. 398-402
[3.]
American Gastroenterological Association medical position statement: celiac sprue Gastroenterology 120 2001 1522-1525.
[4.]
J.A. Walker-Smith, S. Guandalini, J. Schmitz, et al.
Revised criteria for diagnosis of coeliac disease.
Arch Dis Child, 65 (1990), pp. 909-911
[5.]
M.N. Marsh.
Gluten, major histocompatibility complex, and the small intestine. A molecular and immunologic approach to the spectrum of gluten sensitivity (celiac sprue).
Gastroenterology, 102 (1992), pp. 330-354
[6.]
K. Rostami, J. Kerckhaert, R. Tiemessen, et al.
The relationship between antiendomysium antibodies and villous atrophy in celiac disease using both monkey and human substrate.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 439-442
[7.]
M. Hayat, A. Cairns, M.F. Dixon, et al.
Quantitation of intraepithelial lymphocytes in human duodenum: what is normal?.
J Clin Pathol, 55 (2002), pp. 393-395
[8.]
G. Oberhuber, G. Granditsch, H. Vogelsang.
The histopathology of celiac disease: time for a standardized report scheme for pathologists.
Eur J Gastroenterol Hepatol, 11 (1999), pp. 1185-1194
[9.]
A. Polvi, E. Arranz, M. Fernández-Arquero, et al.
HLA-DQ2 negative celiac disease in Finland and Spain.
Hum Immunol, 59 (1998), pp. 169-175
[10.]
K. Karell, A.S. Louka, S.J. Moodie, et al.
HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European genetics cluster on celiac disease.
Human Immunol, 64 (2003), pp. 469-477
[11.]
C. Farré.
Malaltia celíaca: marcadors serològics i de predisposició genètica, aspectes clínics i poblacions de risc [tesis doctoral].
Universidad de Barcelona, (2002),
[12.]
R.FA. Logan.
Problems and pitfalls in epidemiological studies of coeliac disease.
Dyn Nutr Res, 2 (1992), pp. 14-24
[13.]
R.B. Colletti.
The effect of prevalence on the value of serological tests for celiac disease.
J Pediatr Gastroenterol Nutr, 31 (2000), pp. 11
[14.]
E. Fabiani, L.M. Taccari, I.M. Rätsch, S. Di Giuseppe, C.V. Coppa, C. Catassi.
Compliance with gluten-free diet in adolescents with screening-detected celiac disease: a 5-year follow-up study.
J Pediatr, 136 (2000), pp. 841-843
[15.]
H. Hin, G. Bird, P. Fisher, N. Mahy, D. Jewell.
Coeliac disease in primary care: case finding study.
BMJ, 318 (1999), pp. 164-167
[16.]
R.J. Farrell, C.P. Kelly.
Celiac sprue and refractory sprue.
Sleinsenger and Fordtran’s gastrointestinal and liver disease, pp. 1817-1841
[17.]
A. Tursi, G. Giorgetti, G. Brabdimarte, E. Rubino, D. Lombardi, G. Gasbarrini.
Prevalence and clinical presentation of subclinical/ silent disease in adults. An analisys on a 12-year observation.
Hepatogastroenterology, 48 (2001), pp. 462-464
[18.]
J.A. Murray, J. Herlein, F. Mitros, J. Goeken.
Serologic testing for celiac disease in the United States: results of a multilaboratory comparison study.
Clin Diagn Lab Immunol, 7 (2000), pp. 584-587
[19.]
R.C.W. Wong, R.J. Wilson, R.H. Steele, et al.
A comparison of 13 guinea pig and human anti-tissue transglutaminase antibody ELISA kits.
J Clin Pathol, 55 (2002), pp. 488-494
[20.]
K. Rostami, J. Kerckhaert, R. Tiemessen, et al.
Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice.
Am J Gastroenterol, 94 (1999), pp. 888-894
[21.]
A. Tursi, G. Brandimarte, G. Giorgetti, et al.
Low prevalence of antigliadin and antiendomysium antibodies in subclinical/silent celiac disease.
Am J Gastroenterol, 96 (2001), pp. 1507-1510
[22.]
W. Dickey, D.F. Hughes, S.A. McMillan.
Reliance on serum endomysial antibody testing underestimates the true prevalence of coeliac disease by one fifth.
Scand J Gastroenterol, 95 (2000), pp. 712-714
[23.]
P.J. Wahab, J.W.R. Meijer, M.S. Goerres, et al.
Coeliac disease: changing views on gluten-sensitive enteropathy.
Scand J Gastroenterol, 236 (2002), pp. 60-65
[24.]
A. Tursi, G. Brandimarte.
The symptomatic and histologic response to a gluten-free diet in patients with borderline enteropathy.
J Clin Gastroenterol, 36 (2003), pp. 13-17
[25.]
A. Picarelli, L. Maiuri, C. Mazzilli, et al.
Gluten-sensitive disease with mild enteropathy.
Gastroenterology, 111 (1996), pp. 608-616
[26.]
U. Wahnschaffe, R. Ullrich, E.O. Riecken, et al.
Celiac diseaselike abnormalities in a subgroup of patients with irritable bowel syndrome.
Gastroenterology, 121 (2001), pp. 1329-1338
[27.]
M. Esteve, F. Fernández-Bañares, M. Rosinach, et al.
Celiac disease: should be patients with Marsh I (lymphocytic enteritis) be treated with a gluten-free diet.
Gastroenterology, 126 (2004), pp. 246A
[28.]
P.J. Ciclitira.
AGA technical review on celiac sprue.
Gastroenterology, 20 (2001), pp. 1526-1540
[29.]
F. Fernández-Bañares, M. Esteve, M. Alsina, J. Casalots, C. Farré, M. Buzeda, et al.
Systematic assessment of the causes of watery chronic diarrhea with clinical characteristics suggesting functional disease.
Gastroenterology, 126 (2004), pp. 251A
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos